| Characteristic . | Total (n = 93) n (%) . | Patients who underwent hepatectomy (n = 44), n (%) . | Patients who did not undergo hepatectomy (n = 49), n (%) . | P-value . |
|---|---|---|---|---|
| Age (years) | 54.5 ± 9.3 | 54.5 ± 10.6 | 54.5 ± 8.0 | .978 |
| Sex (male/female) | 86 (92.5)/7 (7.5) | 41 (93.2)/3 (6.8) | 45 (91.8)/4 (8.2) | 1.000 |
| Etiology (HBV/HCV/non-viral) | 84(90.3)/2(2.2)/7(7.5) | 38 (86.4)/1 (2.3)/5 (11.4) | 46 (93.9)/1 (2.0)/2 (4.1) | .410 |
| ECOG performance status (0/1) | 52 (55.9)/41 (44.1) | 29 (65.9)/15 (34.1) | 23 (46.9)/26 (53.1) | .066 |
| Liver cirrhosis (present/absent) | 68 (73.1)/25 (26.9) | 29 (63.6)/15 (36.4) | 39 (81.6)/10 (18.4) | .137 |
| TBil (µmol/L) | 16.1 (12.1-21.7) | 16.4 (11.7-23.4) | 15.8 (12.5-20.6) | .814 |
| ALB (g/L) | 40.0 ± 4.5 | 40.5 ± 4.9 | 39.6 ± 4.1 | .319 |
| ALT (U/L) | 41 (28-64) | 45 (25.8-66.3) | 39 (28-62) | .749 |
| AST (U/L) | 48 (31-70) | 44 (26.5-71.0) | 49 (34-71) | .579 |
| PLT (*109/L) | 156 (118–192) | 157.5 (126-232.5) | 140 (108.5-181.5) | .074 |
| HGB (g/L) | 141.2 ± 22.7 | 145.1 ± 22.8 | 137.7 ± 22.2 | .118 |
| PT (s) | 12.2 (11.5-13.1) | 12.0 (11.4-13.2) | 12.2 (11.6-12.9) | .923 |
| Child-Pugh class (A/B) | 82 (88.2)/11 (11.8) | 39 (88.6)/5 (11.4) | 43 (87.8)/6 (12.2) | .895 |
| Baseline AFP (<400/≥400 ng/mL) | 52 (55.9)/41 (44.1) | 22 (50.0)/ 22 (50.0) | 30 (61.2)/19 (38.8) | .276 |
| Baseline PIVKA-II (<400/≥400 mAU/mL) | 24 (25.8)/69 (74.2) | 12 (27.3)/32 (72.7) | 12 (24.5)/37 (75.5) | .759 |
| Tumor number (single/multiple) | 53 (57.0)/40 (43.0) | 27 (61.4)/17 (38.6) | 26 (53.1)/23 (46.9) | .419 |
| Tumor diameter (cm) | 10.1 ± 3.2 | 10.4 ± 3.2 | 9.9 ± 3.2 | .490 |
| Tumor diameter (<10/≥10 cm) | 47 (50.5)/46 (49.5) | 19 (43.2)/25 (56.8) | 28 (57.1)/21 (42.9) | .179 |
| PVTT Cheng’s type (II/III-IV) | 42 (45.2)/51 (54.8) | 22 (50.0)/22 (50.0) | 20 (40.8)/29 (59.2) | .374 |
| Adjuvant therapy following salvage surgery | — | 26 (59.1)/18 (40.9) | — | — |
| Characteristic . | Total (n = 93) n (%) . | Patients who underwent hepatectomy (n = 44), n (%) . | Patients who did not undergo hepatectomy (n = 49), n (%) . | P-value . |
|---|---|---|---|---|
| Age (years) | 54.5 ± 9.3 | 54.5 ± 10.6 | 54.5 ± 8.0 | .978 |
| Sex (male/female) | 86 (92.5)/7 (7.5) | 41 (93.2)/3 (6.8) | 45 (91.8)/4 (8.2) | 1.000 |
| Etiology (HBV/HCV/non-viral) | 84(90.3)/2(2.2)/7(7.5) | 38 (86.4)/1 (2.3)/5 (11.4) | 46 (93.9)/1 (2.0)/2 (4.1) | .410 |
| ECOG performance status (0/1) | 52 (55.9)/41 (44.1) | 29 (65.9)/15 (34.1) | 23 (46.9)/26 (53.1) | .066 |
| Liver cirrhosis (present/absent) | 68 (73.1)/25 (26.9) | 29 (63.6)/15 (36.4) | 39 (81.6)/10 (18.4) | .137 |
| TBil (µmol/L) | 16.1 (12.1-21.7) | 16.4 (11.7-23.4) | 15.8 (12.5-20.6) | .814 |
| ALB (g/L) | 40.0 ± 4.5 | 40.5 ± 4.9 | 39.6 ± 4.1 | .319 |
| ALT (U/L) | 41 (28-64) | 45 (25.8-66.3) | 39 (28-62) | .749 |
| AST (U/L) | 48 (31-70) | 44 (26.5-71.0) | 49 (34-71) | .579 |
| PLT (*109/L) | 156 (118–192) | 157.5 (126-232.5) | 140 (108.5-181.5) | .074 |
| HGB (g/L) | 141.2 ± 22.7 | 145.1 ± 22.8 | 137.7 ± 22.2 | .118 |
| PT (s) | 12.2 (11.5-13.1) | 12.0 (11.4-13.2) | 12.2 (11.6-12.9) | .923 |
| Child-Pugh class (A/B) | 82 (88.2)/11 (11.8) | 39 (88.6)/5 (11.4) | 43 (87.8)/6 (12.2) | .895 |
| Baseline AFP (<400/≥400 ng/mL) | 52 (55.9)/41 (44.1) | 22 (50.0)/ 22 (50.0) | 30 (61.2)/19 (38.8) | .276 |
| Baseline PIVKA-II (<400/≥400 mAU/mL) | 24 (25.8)/69 (74.2) | 12 (27.3)/32 (72.7) | 12 (24.5)/37 (75.5) | .759 |
| Tumor number (single/multiple) | 53 (57.0)/40 (43.0) | 27 (61.4)/17 (38.6) | 26 (53.1)/23 (46.9) | .419 |
| Tumor diameter (cm) | 10.1 ± 3.2 | 10.4 ± 3.2 | 9.9 ± 3.2 | .490 |
| Tumor diameter (<10/≥10 cm) | 47 (50.5)/46 (49.5) | 19 (43.2)/25 (56.8) | 28 (57.1)/21 (42.9) | .179 |
| PVTT Cheng’s type (II/III-IV) | 42 (45.2)/51 (54.8) | 22 (50.0)/22 (50.0) | 20 (40.8)/29 (59.2) | .374 |
| Adjuvant therapy following salvage surgery | — | 26 (59.1)/18 (40.9) | — | — |
Abbreviations: AFP, alpha-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, eastern cooperative oncology group; HBV, hepatitis B virus; HCV, hepatitis C virus; HGB, hemoglobin; PIVKA-II, protein induced by vitamin K absence or antagonist II; PLT, platelet; PT, prothrombin time; PVTT, portal vein tumor thrombus; TBil, total bilirubin.
| Characteristic . | Total (n = 93) n (%) . | Patients who underwent hepatectomy (n = 44), n (%) . | Patients who did not undergo hepatectomy (n = 49), n (%) . | P-value . |
|---|---|---|---|---|
| Age (years) | 54.5 ± 9.3 | 54.5 ± 10.6 | 54.5 ± 8.0 | .978 |
| Sex (male/female) | 86 (92.5)/7 (7.5) | 41 (93.2)/3 (6.8) | 45 (91.8)/4 (8.2) | 1.000 |
| Etiology (HBV/HCV/non-viral) | 84(90.3)/2(2.2)/7(7.5) | 38 (86.4)/1 (2.3)/5 (11.4) | 46 (93.9)/1 (2.0)/2 (4.1) | .410 |
| ECOG performance status (0/1) | 52 (55.9)/41 (44.1) | 29 (65.9)/15 (34.1) | 23 (46.9)/26 (53.1) | .066 |
| Liver cirrhosis (present/absent) | 68 (73.1)/25 (26.9) | 29 (63.6)/15 (36.4) | 39 (81.6)/10 (18.4) | .137 |
| TBil (µmol/L) | 16.1 (12.1-21.7) | 16.4 (11.7-23.4) | 15.8 (12.5-20.6) | .814 |
| ALB (g/L) | 40.0 ± 4.5 | 40.5 ± 4.9 | 39.6 ± 4.1 | .319 |
| ALT (U/L) | 41 (28-64) | 45 (25.8-66.3) | 39 (28-62) | .749 |
| AST (U/L) | 48 (31-70) | 44 (26.5-71.0) | 49 (34-71) | .579 |
| PLT (*109/L) | 156 (118–192) | 157.5 (126-232.5) | 140 (108.5-181.5) | .074 |
| HGB (g/L) | 141.2 ± 22.7 | 145.1 ± 22.8 | 137.7 ± 22.2 | .118 |
| PT (s) | 12.2 (11.5-13.1) | 12.0 (11.4-13.2) | 12.2 (11.6-12.9) | .923 |
| Child-Pugh class (A/B) | 82 (88.2)/11 (11.8) | 39 (88.6)/5 (11.4) | 43 (87.8)/6 (12.2) | .895 |
| Baseline AFP (<400/≥400 ng/mL) | 52 (55.9)/41 (44.1) | 22 (50.0)/ 22 (50.0) | 30 (61.2)/19 (38.8) | .276 |
| Baseline PIVKA-II (<400/≥400 mAU/mL) | 24 (25.8)/69 (74.2) | 12 (27.3)/32 (72.7) | 12 (24.5)/37 (75.5) | .759 |
| Tumor number (single/multiple) | 53 (57.0)/40 (43.0) | 27 (61.4)/17 (38.6) | 26 (53.1)/23 (46.9) | .419 |
| Tumor diameter (cm) | 10.1 ± 3.2 | 10.4 ± 3.2 | 9.9 ± 3.2 | .490 |
| Tumor diameter (<10/≥10 cm) | 47 (50.5)/46 (49.5) | 19 (43.2)/25 (56.8) | 28 (57.1)/21 (42.9) | .179 |
| PVTT Cheng’s type (II/III-IV) | 42 (45.2)/51 (54.8) | 22 (50.0)/22 (50.0) | 20 (40.8)/29 (59.2) | .374 |
| Adjuvant therapy following salvage surgery | — | 26 (59.1)/18 (40.9) | — | — |
| Characteristic . | Total (n = 93) n (%) . | Patients who underwent hepatectomy (n = 44), n (%) . | Patients who did not undergo hepatectomy (n = 49), n (%) . | P-value . |
|---|---|---|---|---|
| Age (years) | 54.5 ± 9.3 | 54.5 ± 10.6 | 54.5 ± 8.0 | .978 |
| Sex (male/female) | 86 (92.5)/7 (7.5) | 41 (93.2)/3 (6.8) | 45 (91.8)/4 (8.2) | 1.000 |
| Etiology (HBV/HCV/non-viral) | 84(90.3)/2(2.2)/7(7.5) | 38 (86.4)/1 (2.3)/5 (11.4) | 46 (93.9)/1 (2.0)/2 (4.1) | .410 |
| ECOG performance status (0/1) | 52 (55.9)/41 (44.1) | 29 (65.9)/15 (34.1) | 23 (46.9)/26 (53.1) | .066 |
| Liver cirrhosis (present/absent) | 68 (73.1)/25 (26.9) | 29 (63.6)/15 (36.4) | 39 (81.6)/10 (18.4) | .137 |
| TBil (µmol/L) | 16.1 (12.1-21.7) | 16.4 (11.7-23.4) | 15.8 (12.5-20.6) | .814 |
| ALB (g/L) | 40.0 ± 4.5 | 40.5 ± 4.9 | 39.6 ± 4.1 | .319 |
| ALT (U/L) | 41 (28-64) | 45 (25.8-66.3) | 39 (28-62) | .749 |
| AST (U/L) | 48 (31-70) | 44 (26.5-71.0) | 49 (34-71) | .579 |
| PLT (*109/L) | 156 (118–192) | 157.5 (126-232.5) | 140 (108.5-181.5) | .074 |
| HGB (g/L) | 141.2 ± 22.7 | 145.1 ± 22.8 | 137.7 ± 22.2 | .118 |
| PT (s) | 12.2 (11.5-13.1) | 12.0 (11.4-13.2) | 12.2 (11.6-12.9) | .923 |
| Child-Pugh class (A/B) | 82 (88.2)/11 (11.8) | 39 (88.6)/5 (11.4) | 43 (87.8)/6 (12.2) | .895 |
| Baseline AFP (<400/≥400 ng/mL) | 52 (55.9)/41 (44.1) | 22 (50.0)/ 22 (50.0) | 30 (61.2)/19 (38.8) | .276 |
| Baseline PIVKA-II (<400/≥400 mAU/mL) | 24 (25.8)/69 (74.2) | 12 (27.3)/32 (72.7) | 12 (24.5)/37 (75.5) | .759 |
| Tumor number (single/multiple) | 53 (57.0)/40 (43.0) | 27 (61.4)/17 (38.6) | 26 (53.1)/23 (46.9) | .419 |
| Tumor diameter (cm) | 10.1 ± 3.2 | 10.4 ± 3.2 | 9.9 ± 3.2 | .490 |
| Tumor diameter (<10/≥10 cm) | 47 (50.5)/46 (49.5) | 19 (43.2)/25 (56.8) | 28 (57.1)/21 (42.9) | .179 |
| PVTT Cheng’s type (II/III-IV) | 42 (45.2)/51 (54.8) | 22 (50.0)/22 (50.0) | 20 (40.8)/29 (59.2) | .374 |
| Adjuvant therapy following salvage surgery | — | 26 (59.1)/18 (40.9) | — | — |
Abbreviations: AFP, alpha-fetoprotein; ALB, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, eastern cooperative oncology group; HBV, hepatitis B virus; HCV, hepatitis C virus; HGB, hemoglobin; PIVKA-II, protein induced by vitamin K absence or antagonist II; PLT, platelet; PT, prothrombin time; PVTT, portal vein tumor thrombus; TBil, total bilirubin.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
